No recent mentions
Hims & Hers Stock Surges 14% as FDA Plans Review of Peptide Compounding Eligibility
Hims & Hers stock rose 14% after the FDA scheduled a review of peptide compounding eligibility, a move that could open new market prospects. The outcome of the review in July will impact the company's growth trajectory and competitive positioning.
· 49d ago
Hims & Hers and Novo Nordisk End GLP-1 Dispute Amid Rumors of Collaboration
Hims & Hers resolves its dispute with Novo Nordisk over Wegovy, coinciding with legal scrutiny over its Semaglutide claims. The company's stock surges amid rumors of a new collaboration with Novo Nordisk, signaling a potential strategic move in the market.
· 87d ago